Longitude Capital Partners III, LLC's Net Worth

$280 Million

Who is Longitude Capital Partners III, LLC?

Longitude Capital Partners III, LLC has an estimated net worth of $280 Million. This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Axonics Modulation Technologies, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., 89bio, Inc., and Molecular Templates, Inc..

SEC CIK

Longitude Capital Partners III, LLC's CIK is 0001713663

Past Insider Trading and Trends

2020 was Longitude Capital Partners III, LLC's most active year for acquiring shares with 11 total transactions. Longitude Capital Partners III, LLC's most active month to acquire stocks was the month of October. 2020 was Longitude Capital Partners III, LLC's most active year for disposing of shares, totalling 7 transactions. Longitude Capital Partners III, LLC's most active month to dispose stocks was the month of April. 2020 saw Longitude Capital Partners III, LLC paying a total of $12,999,975.00 for 4,418,724 shares, this is the most they've acquired in one year. In 2022 Longitude Capital Partners III, LLC cashed out on 3,616,896 shares for a total of $19,498,050.00, their largest year based on trade value.